Charles River Laboratories International (NYSE:CRL) Announces Quarterly Earnings Results, Beats Estimates By $0.28 EPS

Charles River Laboratories International (NYSE:CRL) released its quarterly earnings data on Wednesday. The medical research company reported $3.02 EPS for the quarter, topping the consensus estimate of $2.74 by $0.28, Briefing.com reports. The company had revenue of $1 billion for the quarter, compared to the consensus estimate of $977.20 million. Charles River Laboratories International had a positive return on equity of 15.36% and a negative net margin of 4.59%.Charles River Laboratories International’s quarterly revenue was down 2.7% on a year-over-year basis. During the same period last year, the business posted $3.12 EPS. Charles River Laboratories International updated its FY 2026 guidance to 11.150-11.450 EPS.

Here are the key takeaways from Charles River Laboratories International’s conference call:

• Charles River raised its 2026 outlook, now projecting flat to 1% organic revenue growth and non-GAAP EPS of $11.15–$11.45, up $0.25 at the midpoint from prior guidance.
• DSA demand improved materially, with second-quarter net bookings rising 12.6% sequentially to $701 million, backlog reaching $1.97 billion, and net book-to-bill increasing to 1.19 times. Management expects DSA organic growth to accelerate in the second half.
• Portfolio divestitures and lower non-human-primate sourcing costs are expected to drive at least 500 basis points of operating-margin improvement in the second half, while manufacturing margins are expected to approach 40%.
• RMS revenue declined 1.4% organically, pressured by weaker North American research-model volumes and constrained academic and government spending; management continues to forecast a low- to mid-single-digit organic decline for the segment in 2026.
• A higher expected tax rate of 23%–24%, partly tied to proposed legislation in Mauritius, is expected to create an approximately $0.20 per-share EPS headwind for the year, although a lower-than-expected change could provide upside.

Charles River Laboratories International Stock Up 11.1%

Shares of Charles River Laboratories International stock traded up $26.04 on Wednesday, reaching $260.16. The stock had a trading volume of 1,322,243 shares, compared to its average volume of 920,136. Charles River Laboratories International has a 1 year low of $144.26 and a 1 year high of $267.99. The company has a 50 day moving average price of $209.54 and a 200 day moving average price of $188.12. The company has a quick ratio of 1.03, a current ratio of 1.36 and a debt-to-equity ratio of 0.90. The stock has a market capitalization of $12.53 billion, a P/E ratio of -69.26, a P/E/G ratio of 2.57 and a beta of 1.38.

Insider Transactions at Charles River Laboratories International

In other news, Director James C. Foster sold 75,000 shares of the company’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $225.00, for a total transaction of $16,875,000.00. Following the transaction, the director directly owned 31,596 shares of the company’s stock, valued at approximately $7,109,100. This represents a 70.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 1.30% of the company’s stock.

Institutional Investors Weigh In On Charles River Laboratories International

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CRL. Invesco Ltd. grew its stake in shares of Charles River Laboratories International by 115.8% during the fourth quarter. Invesco Ltd. now owns 2,696,150 shares of the medical research company’s stock worth $537,828,000 after acquiring an additional 1,446,972 shares during the last quarter. Victory Capital Management Inc. raised its position in shares of Charles River Laboratories International by 9,938.8% in the 4th quarter. Victory Capital Management Inc. now owns 691,474 shares of the medical research company’s stock valued at $137,935,000 after purchasing an additional 684,586 shares during the last quarter. Ameriprise Financial Inc. grew its position in Charles River Laboratories International by 1,491.1% during the 3rd quarter. Ameriprise Financial Inc. now owns 613,604 shares of the medical research company’s stock worth $96,005,000 after purchasing an additional 575,039 shares during the last quarter. Balyasny Asset Management L.P. increased its stake in Charles River Laboratories International by 722.5% during the 2nd quarter. Balyasny Asset Management L.P. now owns 434,226 shares of the medical research company’s stock valued at $65,885,000 after purchasing an additional 381,432 shares in the last quarter. Finally, Alyeska Investment Group L.P. raised its holdings in shares of Charles River Laboratories International by 120.7% in the fourth quarter. Alyeska Investment Group L.P. now owns 644,726 shares of the medical research company’s stock worth $128,610,000 after buying an additional 352,549 shares during the last quarter. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on CRL. JPMorgan Chase & Co. dropped their price target on Charles River Laboratories International from $165.00 to $160.00 and set a “neutral” rating on the stock in a research report on Monday, April 13th. Evercore reissued an “outperform” rating and set a $220.00 target price on shares of Charles River Laboratories International in a research report on Friday, May 8th. Weiss Ratings upgraded shares of Charles River Laboratories International from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 1st. Mizuho upped their price target on shares of Charles River Laboratories International from $192.00 to $230.00 and gave the stock a “neutral” rating in a research report on Monday, July 13th. Finally, Barclays lifted their price objective on shares of Charles River Laboratories International from $210.00 to $220.00 and gave the company an “overweight” rating in a report on Friday, May 8th. Eleven investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $220.75.

Key Charles River Laboratories International News

Here are the key news stories impacting Charles River Laboratories International this week:

• Positive Sentiment: CRL reported second-quarter adjusted earnings of $3.02 per share, exceeding analyst estimates of approximately $2.72–$2.74. Revenue of about $1.0 billion also surpassed the roughly $977 million consensus. CRL Q2 Earnings and Revenues Top, 2026 View Up
• Positive Sentiment: The company raised its FY 2026 adjusted EPS outlook to $11.15–$11.45, above the prior consensus near $11.09, and issued revenue guidance of approximately $3.9 billion, ahead of Wall Street expectations. Charles River lifts profit forecast on improving biotech demand
• Positive Sentiment: Management cited improving demand from biotechnology customers for drug discovery and development services, along with a positive inflection in order trends. The Discovery and Safety Assessment segment reportedly has a strong backlog and book-to-bill ratio. CRL Q2 2026 Earnings Call Transcript
• Positive Sentiment: Margin expansion is expected to benefit from cost reductions and recent divestitures, supporting the higher profit outlook even as the company targets only slightly positive organic revenue growth. Charles River: Near-Term Inflection But Long-Term Risk
• Neutral Sentiment: The earnings beat was partly offset by comparisons with a strong prior-year quarter, making execution and sustained biotech demand important for validating the recovery.
• Negative Sentiment: Second-quarter revenue declined 2.7% year over year, while EPS fell from $3.12 a year earlier. Research Models and Services continues to face weakness in the United States, despite strength in China, leaving longer-term growth risks. CRL Q2 Key Metrics Versus Estimates

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.